Key facts
- It has raised $178.5M across 5 recorded rounds; the latest was Later Stage VC (Series C) ($63.5M) in Aug 2024.
- 4 institutional filers report fund marks on MBX Biosciences across 14 filings.
- MBX Biosciences has filed 4 Form Ds with the SEC since 2019, most recently Nov 2022 ($46.7M sold to 20 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 5 rounds
- ·Watchlist + deal alerts for MBX Biosciences
Create free account
No card required
Funding rounds
5 roundsAug 2024Later Stage VC (Series C)$63.5M▮
Nov 2022Early Stage VC (Series B)$115.0M▮
Jan 2022Seed Round—▮
About MBX Biosciences
- Industry
- Drug Discovery
PA Mark — not yet priced
MBX Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in MBX Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 14 fair-value marks on MBX Biosciences between Jul 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.